Indicator Details — Emerging Topics: Cancer Incidence by eGFR Categoriesa
Data Sources
Stratification and Year Choices:

  • Clinical Trials

  View Data By:
  Chart Format

+ View Data Table

a eGFR: estimated glomerular filtration rate adjusted for age, sex, race, and smoking status. Reference group: eGFR ≥ 75 mL/min/1.73 m2

There is ongoing interest in the relationship between chronic kidney disease (CKD) and cancer. Although it is well known that some malignancies may contribute to kidney dysfunction (e.g., multiple myeloma), it is less clear whether CKD, particularly in its earlier stages, contributes to the development of cancer. A recent meta-analysis of data from one cohort study and five clinical trials examined the effect of various levels of estimated glomerular filtration rate (eGFR). Associations were either weak or absent with earlier stages of CKD, and there was substantial variability by site of the cancer.
Chart Explanation: After adjusting for age, sex, race and smoking status, the relative risk of any cancer was not increased significantly for any range of eGFR. By site of cancer, there were significant increases in risk for urinary tract tumors for patients with eGFR < 45 mL/min/1.73 m2 (Hazard Ratio [HR] 1.7; 95% Confidence Interval (CI): 1.0-2.7) and those on dialysis (HR 2.3; 95%CI: 1.3-4.2). 
Six studies were included in our analysis, of which one was a prospective, population-based cohort study, and five were randomized controlled trials (RCTs). These studies were included because they provided details of
serum creatinine, age and gender for the estimation of glomerular filtration rate (GFR), as well as information on site-specific and overall cancer incidence and mortality. Information on non-cancer related mortality was
also recorded. All studies were also available to the investigator team for inclusion and so represent a sample of all possible datasets available for analysis.
Description of MeasureCancer incidence by eGFR categories
Data Source Long NameMeta-analysis based on one cohort study and five clinical trials.
Type of Data SourceLiterature review
Data Source Short NameClinical Trials
Data Source DescriptionSix studies, including one population based cohort and five randomized controled trials.
Health Care System DataNo
Regional or NationalNational
Demographic Groupn/a
Definition of CKDStatus of CKD was defined based on CKD EPI-estimated GFR (ml/min/1.73m2) cut off points as follows:
eGFR ≥ 75 ml/min/1.73m2
60 ≤ eGFR < 75ml/min/1.73m2 
45 ≤ egfr < 60 ml/min/1.73m2
eGFR < 45 ml/min/1.73m2
Glomerular Filtration RateEstimated, CKD-EPI definition
Primary Data Source IndicatorIncidence of cancer by CKD
Primary Data Source IndicatorCKD status by eGFR
Period Current Availablen/a
Frequency of MeasurementOne time
Pending Datan/a
Data SetThe cohort study was the Blue Mountains Eye Study (BMES), which included a suburban Australian population aged 49 years or older at baseline (n = 3654). The other five RCTs included the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) study, a multi-centre trial of blood pressure lowering and glucose control in people with type 2 diabetes mellitus (n = 11,140); the Perindopril-based blood-pressure-lowering regimen (PROGRESS) study, a multi-centre trial of intensive blood pressure lowering using the mixed perindopril and indapamide and placebo in patients with a history of stroke or transient ischaemic attack (n = 6105); the Calcium Intake Fracture Outcome (CAIFOS) study, a trial of 1500 women that assessed the effects of daily calcium supplements and the risk of osteoporotic fractures in post-menopausal women; the Study of Heart and Renal Protection (SHARP), a multi-centre trial of LDL cholesterol lowering in people with CKD (n = 9270) and the Initiating Dialysis Early and Late Study (IDEAL), a trial that compared early and later commencement of dialysis in patients with ESKD (n = 828). Full details of each study are reported elsewhere.
References and Sources:
Suggested Citation:
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States.